Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G7FJ
|
|||
| Former ID |
DIB010390
|
|||
| Drug Name |
Meloxicam
|
|||
| Synonyms |
Meloxicam (SoluMatrix/arthritis); Meloxicam nanoformulation capsules (arthritis), iCeutica; Meloxicam (SoluMatrix/arthritis), iCeutica
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Arthritis [ICD-11: FA20] | Approved | [1], [2], [3] | |
| Company |
Iroko pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H13N3O4S2
|
|||
| Canonical SMILES |
CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O
|
|||
| InChI |
1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,18H,1-2H3,(H,15,16,19)
|
|||
| InChIKey |
ZRVUJXDFFKFLMG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 71125-38-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10369, 855815, 6681236, 7848032, 7979894, 11364527, 11367089, 11369651, 11371577, 11374373, 11377813, 11484638, 11488757, 11490465, 11492602, 11495447, 11528628, 12013466, 14754262, 26612637, 26680359, 26747003, 26747004, 26759123, 29223163, 39290017, 39404337, 42685351, 46506624, 47216906, 47589118, 47589119, 47736629, 48259389, 48413967, 49834840, 50085983, 50100965, 53598948, 53598949, 53598950, 53790511, 56313654, 56320470, 57358017, 81093329, 85087488, 85174237, 87560523, 89736106
|
|||
| ChEBI ID |
CHEBI:6741
|
|||
| ADReCS Drug ID | BADD_D01374 ; BADD_D01375 | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7220). | |||
| REF 2 | ClinicalTrials.gov (NCT02183155) Effect of Meloxicam Tablets on Bleeding Time in Healthy Subjects. U.S. National Institutes of Health. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 4 | Meloxicam: selective COX-2 inhibition in clinical practice. Semin Arthritis Rheum. 1997 Jun;26(6 Suppl 1):21-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.